{ "id": "epdwghb431", "slug": "adoptive-cell-transfer", "title": "Adoptive cell transfer", "updated": "2026-10-15", "topic_path": [ { "id": "life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/topics/life" }, { "id": "life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health" }, { "id": "life.health.clinical", "label": "Clinical assessment and procedures", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical" }, { "id": "life.health.clinical.clinical-transplantation", "label": "Organ and tissue transplantation", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical.clinical-transplantation" }, { "id": "life.health.clinical.clinical-transplantation.alpha-a-to-la", "label": "Titles A to La", "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.clinical.clinical-transplantation.alpha-a-to-la" } ], "geo": [ { "id": "geo.nongeo.t1946.life.health.clinical.clinical-transplantation", "label": "Non-geographic · 1946 to 2000: Organ and tissue transplantation", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.clinical-transplantation", "path": [ { "id": "geo.nongeo", "label": "Non-geographic", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo" }, { "id": "geo.nongeo.t1946", "label": "Non-geographic · 1946 to 2000", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946" }, { "id": "geo.nongeo.t1946.life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life" }, { "id": "geo.nongeo.t1946.life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health" }, { "id": "geo.nongeo.t1946.life.health.clinical", "label": "Clinical assessment and procedures", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical" }, { "id": "geo.nongeo.t1946.life.health.clinical.clinical-transplantation", "label": "Organ and tissue transplantation", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.clinical.clinical-transplantation" } ] }, { "id": "geo.nongeo.t2001.life.health.clinical", "label": "Non-geographic · 2001 to 2020: Clinical assessment and procedures", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life.health.clinical", "path": [ { "id": "geo.nongeo", "label": "Non-geographic", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo" }, { "id": "geo.nongeo.t2001", "label": "Non-geographic · 2001 to 2020", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001" }, { "id": "geo.nongeo.t2001.life", "label": "Life and health", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life" }, { "id": "geo.nongeo.t2001.life.health", "label": "Human health and medicine", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life.health" }, { "id": "geo.nongeo.t2001.life.health.clinical", "label": "Clinical assessment and procedures", "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t2001.life.health.clinical" } ] } ], "excerpt": "Adoptive cell transfer (ACT) is an immunotherapy in which a patient's own or donor immune cells are modified and reinfused to treat cancer, pioneered by Steven Rosenberg in 1985.", "snippet": "Adoptive cell transfer (ACT) is an immunotherapy in which a patient's own or donor immune cells are modified and reinfused to treat cancer, pioneered by Steven Rosenberg in 1985.", "node": "life.health.clinical.clinical-transplantation.alpha-a-to-la", "markdown": "# Adoptive cell transfer\n\nAdoptive cell transfer (ACT) is an immunotherapy in which a patient's own or a donor's immune cells are collected, modified, or expanded outside the body, and reinfused to treat cancer or infection. The term was first proposed in 1985 by [Steven A. Rosenberg](https://www.edgepedia.org/steven-a-rosenberg) and colleagues, who reported in the New England Journal of Medicine that transferring immune cells could generate immunity.[1](https://doi.org/10.1016/j.ymthe.2025.03.005) The modern family spans tumor-infiltrating lymphocyte (TIL) therapy, chimeric antigen receptor T cells (CAR-T), engineered TCR T cells, and engineered natural killer cell products. Autologous TIL therapy mediates objective tumor regressions in about 50% of patients with metastatic melanoma,[2](https://www.nature.com/articles/nrc2355) the first CAR-T product was approved in the United States in August 2017,[3](https://www.ncbi.nlm.nih.gov/books/NBK537294/) and approved autologous CAR-T products cost roughly $300,000 to $500,000 per dose.[4](https://doi.org/10.1016/j.stemcr.2025.102515)\n\n| Key fact | Value |\n|---|---|\n| First US CAR-T approval | Tisagenlecleucel, August 2017, for refractory B-cell precursor ALL; the large B-cell lymphoma indication was approved in May 2018[3](https://www.ncbi.nlm.nih.gov/books/NBK537294/) • [37](https://www.novartis.com/news/media-releases/kymriah-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma) |\n| First TIL and first TCR gene therapy approvals | Lifileucel, February 16, 2024 (melanoma); afamitresgene autoleucel, August 2024 (synovial sarcoma)[5](https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma) • [6](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-metastatic-synovial-sarcoma) |\n| Randomized comparison (ZUMA-7) | Median event-free survival 8.3 vs 2.0 months versus standard care; complete response 65% vs 32%[7](https://www.nejm.org/doi/full/10.1056/NEJMoa2116133) |\n| Typical CAR-T manufacturing turnaround | 13 days (axi-cel, ZUMA-7) to 4–6 weeks order-to-receipt at early European centers[7](https://www.nejm.org/doi/full/10.1056/NEJMoa2116133) • [8](https://www.ncbi.nlm.nih.gov/books/NBK584162/) |\n| Severe toxicities (axi-cel, ZUMA-7) | Grade ≥3 CRS 6%; grade ≥3 neurologic events 21%[7](https://www.nejm.org/doi/full/10.1056/NEJMoa2116133) |\n| Cost per dose (approved autologous CAR-T) | Roughly $300,000 to $500,000[4](https://doi.org/10.1016/j.stemcr.2025.102515) |\n\n## How it works\n\nTransferred cells succeed where a patient's endogenous immunity fails for two main reasons. First, the cells are given in enormous numbers after selection or engineering for tumor recognition. TIL recognize tumor-specific neoantigens through TCR–peptide–HLA (human leukocyte antigen; cell-surface proteins presenting peptide fragments to T cells) engagement and mediate tumor cell lysis; after lifileucel infusion, TCR clonotypes from the product rose from a mean of 16% of the peripheral blood repertoire before infusion to 83% at day 4.[9](https://www.iovance.com/uploads/Lifileucel-Product-Monograph-English-CA.pdf) CARs, by contrast, recognize surface antigens through an antibody-derived single-chain variable fragment, while engineered TCRs can target intracellular antigens presented by HLA.\n\nSecond, lymphodepleting chemotherapy before transfer removes regulatory T cells and competing lymphocytes that consume homeostatic cytokines such as IL-7 and IL-15, giving the transferred cells access to these survival signals.[2](https://www.nature.com/articles/nrc2355) Cell state also matters: CD8+ T cells driven to full effector function in vitro paradoxically show poorer in vivo antitumor efficacy than less differentiated cells,[10](https://doi.org/10.1172/jci24480) and stem-like CD8 T cells mediate the clinical responses of adoptive cell immunotherapy against human cancer.[11](https://doi.org/10.1126/science.abb9847)\n\n## How it is done\n\nThe production process comprises isolation and enrichment of T cells, activation, gene transfer using viral or non-viral vector systems, ex vivo expansion, and end-of-process formulation with cryopreservation, with lymphodepleting treatment before administration.[12](https://www.mdpi.com/1422-0067/20/24/6223) For commercial CAR-T products, cells are shipped frozen in a dry shipper at approximately −160 °C, and turnaround between ordering and receiving is 4–6 weeks at early European centers.[8](https://www.ncbi.nlm.nih.gov/books/NBK584162/)\n\nLymphodepleting chemotherapy is started five to seven days ahead of CAR-[T cell](https://www.edgepedia.org/t-cell) injection.[8](https://www.ncbi.nlm.nih.gov/books/NBK584162/) At infusion, a leukodepleting filter cannot be used, and central venous access is the recommended method.[3](https://www.ncbi.nlm.nih.gov/books/NBK537294/) After CAR-T infusion, patients are monitored daily for at least 7 days and should remain near the certified facility for at least 4 weeks.[3](https://www.ncbi.nlm.nih.gov/books/NBK537294/)\n\n## Origin\n\nDevelopment of recombinant IL-2 enabled large-scale production of the growth factor used in early trials.[13](https://mdpi-res.com/d_attachment/immuno/immuno-01-00012/article_deploy/immuno-01-00012.pdf?version=1625822468) In 1985, Steven A. Rosenberg and colleagues reported in the New England Journal of Medicine that 25 patients with metastatic cancer received autologous lymphokine-activated killer (LAK) cells plus interleukin-2, with objective regression in 11 of 25 patients and one complete melanoma remission sustained up to 10 months.[14](https://doi.org/10.1056/nejm198512053132327) Rosenberg, Paul Spiess, and Rene Lafreniere reported the TIL approach in Science in 1986,[15](https://doi.org/10.1126/science.3489291) and the first in-human TIL study was performed in 1988 in metastatic melanoma, achieving a 55% objective response rate with cyclophosphamide lymphodepletion and adjuvant IL-2.[16](https://jitc.bmj.com/content/9/7/e002723) Rosenberg and colleagues published the TIL plus IL-2 melanoma trial in the New England Journal of Medicine in 1988,[17](https://doi.org/10.1056/nejm198812223192527) and in 1990 reported the first gene transfer into humans using retrovirally modified TIL.[18](https://doi.org/10.1056/nejm199008303230904)\n\nLymphodepletion before transfer was developed clinically in 2005, when Mark E. Dudley and colleagues reported adoptive cell transfer after non-myeloablative but lymphodepleting chemotherapy in refractory metastatic melanoma.[19](https://doi.org/10.1200/jco.2005.00.240) In 2006, Richard A. Morgan and colleagues reported transfer of retrovirally TCR-transduced lymphocytes in 15 melanoma patients, with objective regression in two patients.[20](https://doi.org/10.1126/science.1129003) [James N. Kochenderfer](https://www.edgepedia.org/james-n-kochenderfer) and colleagues reported regression of lymphoma after CD19-directed engineered T cells in 2010,[21](https://doi.org/10.1182/blood-2010-04-281931) and David L. Porter, Bruce L. Levine, Michael Kalos, Adam Bagg, and Carl H. June reported CAR-modified T cells in chronic lymphoid leukemia in 2011.[22](https://doi.org/10.1056/nejmoa1103849) In 2013, [Stephan A. Grupp](https://www.edgepedia.org/stephan-a-grupp) and colleagues reported CAR-modified T cells in acute lymphoid leukemia.[23](https://doi.org/10.1056/nejmoa1215134)\n\nDonor-derived ACT developed in parallel: HJ Kolb and colleagues reported donor leukocyte transfusions for recurrent chronic myelogenous leukemia in 1990,[24](https://doi.org/10.1182/blood.v76.12.2462.2462) Esperanza B. Papadopoulos and colleagues reported donor leukocyte infusions for EBV-associated lymphoproliferative disorders in 1994,[25](https://doi.org/10.1056/nejm199404283301703) and [Cliona M. Rooney](https://www.edgepedia.org/cliona-m-rooney) and colleagues reported EBV-specific cytotoxic T cell infusions in 1998.[26](https://doi.org/10.1182/blood.v92.5.1549)\n\n## Variants\n\nTIL therapy uses T cells harvested from a patient's tumor and expanded ex vivo, without antigen-specific engineering; traditional preparation spans 4–6 weeks and requires surgical tumor acquisition.[27](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1665488/full) CAR-T cells carry a synthetic receptor with an scFv antigen-binding domain plus signaling domains. First-generation CARs lacking a costimulatory domain produced low cytokine secretion, weak expansion, and anergy; second-generation CARs added costimulatory domains such as CD27, CD28, OX40, or 4-1BB, where CD28 supports stronger expansion and tumor eradication while 4-1BB is associated with prolonged persistence and ameliorates exhaustion; third-generation CARs combine two costimulatory domains, and fourth-generation CARs (TRUCKs) release transgenic products such as IL-12 at the tumor site.[12](https://www.mdpi.com/1422-0067/20/24/6223) CAR design was refined by incorporating an scFv alongside the signaling domain, creating the first-generation CAR.[1](https://doi.org/10.1016/j.ymthe.2025.03.005) TCR-engineered T cells carry a natural TCR recognizing peptide-HLA; Kimmtrak ([tebentafusp](https://www.edgepedia.org/tebentafusp)), described as the world's first TCR-based therapy, received FDA approval in 2022 for HLA-A*02:01-positive metastatic uveal melanoma.[27](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1665488/full)\n\n## Applications\n\nTisagenlecleucel (Kymriah) was the first FDA-approved CAR-T treatment in August 2017; it is a CD19-directed autologous T-cell immunotherapy made with a lentiviral vector encoding an anti-CD19 CAR with 4-1BB (CD137) and CD3-zeta signaling domains.[3](https://www.ncbi.nlm.nih.gov/books/NBK537294/) • [28](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aad3ba54-dfd3-4cb3-9e2b-c5ef89559189) Eight CAR-T therapies had been commercially approved, all of them second-generation constructs.[29](https://link.springer.com/article/10.1186/s13045-023-01492-8) On February 16, 2024, the FDA approved Amtagvi (lifileucel), the first tumor-derived T cell immunotherapy, for adults with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody and, if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor.[5](https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma) On August 2, 2024, the FDA approved Tecelra (afamitresgene autoleucel), the first FDA-approved TCR gene therapy, for adults with unresectable or metastatic synovial sarcoma whose tumor expresses MAGE-A4.[6](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-metastatic-synovial-sarcoma) Donor lymphocyte ACT is also an effective treatment for post-transplant lymphomas.[2](https://www.nature.com/articles/nrc2355)\n\nIn the randomized ZUMA-7 trial, axi-cel gave a median event-free survival of 8.3 vs 2.0 months versus standard care, with complete response 65% vs 32%.[7](https://www.nejm.org/doi/full/10.1056/NEJMoa2116133) Among 73 patients treated with lifileucel at the recommended dose, the objective response rate was 31.5%, including three complete and 20 partial responses.[5](https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma) Among 44 patients who received Tecelra, the overall response rate was 43.2% and median duration of response six months.[6](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-metastatic-synovial-sarcoma)\n\n## Limitations and alternatives\n\n[Cytokine release syndrome](https://www.edgepedia.org/cytokine-release-syndrome) (CRS) is the most common adverse effect of CAR-T therapy, typically occurring within the first week and peaking within 1 to 2 weeks of cell administration.[3](https://www.ncbi.nlm.nih.gov/books/NBK537294/) In the tisagenlecleucel label, CRS occurred in 61 of 79 (77%) pediatric and young adult ALL patients, including grade ≥3 in 48%; the label carries a boxed warning for CRS, neurologic toxicities, and secondary hematological malignancies.[28](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aad3ba54-dfd3-4cb3-9e2b-c5ef89559189) In ZUMA-7, grade ≥3 adverse events occurred in 91% of axi-cel patients, with grade ≥3 CRS in 6% and grade ≥3 neurologic events in 21%.[7](https://www.nejm.org/doi/full/10.1056/NEJMoa2116133)\n\nFailure modes include antigen escape: in the seminal tisagenlecleucel trial, 94% of assessed relapsed B-ALL patients who relapsed had CD19 antigen loss through genetic mutation or isoforms lacking the transmembrane domain or targeted exon.[16](https://jitc.bmj.com/content/9/7/e002723) Exhausted CAR-T cells show upregulated inhibitory receptors (PD-1, Lag3, Tim3, TIGIT), decreased secretion of IL-2, TNF-α, and IFN-γ, altered metabolism, and epigenetic modifications.[29](https://link.springer.com/article/10.1186/s13045-023-01492-8) Solid tumors remain difficult: in an anti-EGFRvIII CAR-T trial for recurrent glioblastoma, 0 of 10 patients achieved partial or complete response despite preclinical efficacy.[29](https://link.springer.com/article/10.1186/s13045-023-01492-8)\n\nAllogeneic and next-generation ACT is advancing: cema-cel, an allogeneic CD19 CAR-T, achieved 58% overall response and 42% complete response with no grade ≥3 CRS, ICANS, or GvHD in 33 CAR-naive patients with relapsed/refractory large [B-cell lymphoma](https://www.edgepedia.org/b-cell-lymphoma).[30](https://link.springer.com/article/10.1186/s13045-025-01737-8) Gene editing is moving toward off-the-shelf products: Edward A. Stadtmauer and colleagues reported the first-in-human multiplex CRISPR-engineered T cells in 2020,[31](https://doi.org/10.1126/science.aba7365) and Robert Chiesa and colleagues reported the first clinical application of base editing to generate multiplexed universal CAR7 T cells for relapsed [T-cell acute lymphoblastic leukemia](https://www.edgepedia.org/t-cell-acute-lymphoblastic-leukemia) in 2023.[32](https://doi.org/10.1056/nejmoa2300709) Exhaustion-resistance engineering includes c-Jun overexpression,[33](https://doi.org/10.1038/s41586-019-1805-z) and RASA2 ablation, which boosts antigen sensitivity and long-term function.[34](https://doi.org/10.1038/s41586-022-05126-w) In solid tumors, IL-15-armored GPC3-targeted CAR T cells showed enhanced in vivo proliferation and persistence with objective responses,[35](https://doi.org/10.1038/s41586-024-08261-8) and GD2-targeted CAR T cells mediated meaningful clinical and radiographic responses in H3K27M+ diffuse midline gliomas.[36](https://doi.org/10.1038/s41586-024-08171-9)\n\n## References\n\n1. [From concept to cure: The evolution of CAR-T cell therapy (Molecular Therapy, 2025)](https://doi.org/10.1016/j.ymthe.2025.03.005)\n2. [Adoptive cell transfer: a clinical path to effective cancer immunotherapy | Nature Reviews Cancer](https://www.nature.com/articles/nrc2355)\n3. [Chimeric Antigen Receptor T-Cell Therapy (StatPearls)](https://www.ncbi.nlm.nih.gov/books/NBK537294/)\n4. [Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform (Stem Cell Reports, 2025)](https://doi.org/10.1016/j.stemcr.2025.102515)\n5. [FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma](https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma)\n6. [FDA Approves First Gene Therapy to Treat Adults with Metastatic Synovial Sarcoma](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-metastatic-synovial-sarcoma)\n7. [Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma (ZUMA-7)](https://www.nejm.org/doi/full/10.1056/NEJMoa2116133)\n8. [Receiving, Handling, Storage, Thawing, Distribution, and Administration of CAR-T Cells (EBMT/EHA CAR-T Cell Handbook)](https://www.ncbi.nlm.nih.gov/books/NBK584162/)\n9. [AMTAGVI (lifileucel) Canadian Product Monograph](https://www.iovance.com/uploads/Lifileucel-Product-Monograph-English-CA.pdf)\n10. [L. Gattinoni (2005). Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. Journal of Clinical Investigation.](https://doi.org/10.1172/jci24480)\n11. [Sri Krishna and colleagues (2020). Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science.](https://doi.org/10.1126/science.abb9847)\n12. [Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy (Int. J. Mol. Sci.)](https://www.mdpi.com/1422-0067/20/24/6223)\n13. [ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors (Immuno)](https://mdpi-res.com/d_attachment/immuno/immuno-01-00012/article_deploy/immuno-01-00012.pdf?version=1625822468)\n14. [Steven A. Rosenberg and colleagues (1985). Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer. New England Journal of Medicine.](https://doi.org/10.1056/nejm198512053132327)\n15. [Steven A. Rosenberg, Paul Spiess, Rene Lafreniere (1986). A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes. Science.](https://doi.org/10.1126/science.3489291)\n16. [Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead (Journal for ImmunoTherapy of Cancer)](https://jitc.bmj.com/content/9/7/e002723)\n17. [Steven A. Rosenberg and colleagues (1988). Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma. New England Journal of Medicine.](https://doi.org/10.1056/nejm198812223192527)\n18. [Steven A. Rosenberg and colleagues (1990). Gene Transfer into Humans, Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction. New England Journal of Medicine.](https://doi.org/10.1056/nejm199008303230904)\n19. [Mark E. Dudley and colleagues (2005). Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma. Journal of Clinical Oncology.](https://doi.org/10.1200/jco.2005.00.240)\n20. [Richard A. Morgan and colleagues (2006). Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science.](https://doi.org/10.1126/science.1129003)\n21. [James N. Kochenderfer and colleagues (2010). Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood.](https://doi.org/10.1182/blood-2010-04-281931)\n22. [David L. Porter and colleagues (2011). Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia. New England Journal of Medicine.](https://doi.org/10.1056/nejmoa1103849)\n23. [Stephan A. Grupp and colleagues (2013). Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia. New England Journal of Medicine.](https://doi.org/10.1056/nejmoa1215134)\n24. [HJ Kolb and colleagues (1990). Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood.](https://doi.org/10.1182/blood.v76.12.2462.2462)\n25. [Esperanza B. Papadopoulos and colleagues (1994). Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation. New England Journal of Medicine.](https://doi.org/10.1056/nejm199404283301703)\n26. [Cliona M. Rooney and colleagues (1998). Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients. Blood.](https://doi.org/10.1182/blood.v92.5.1549)\n27. [Recent advances in adoptive cell therapy for cancer immunotherapy (Frontiers in Immunology)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1665488/full)\n28. [KYMRIAH (tisagenlecleucel) FDA prescribing information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aad3ba54-dfd3-4cb3-9e2b-c5ef89559189)\n29. [Challenges and new technologies in adoptive cell therapy (Journal of Hematology & Oncology)](https://link.springer.com/article/10.1186/s13045-023-01492-8)\n30. [Recent advances in universal chimeric antigen receptor T cell therapy (Journal of Hematology & Oncology)](https://link.springer.com/article/10.1186/s13045-025-01737-8)\n31. [Edward A. Stadtmauer and colleagues (2020). CRISPR-engineered T cells in patients with refractory cancer. Science.](https://doi.org/10.1126/science.aba7365)\n32. [Robert Chiesa and colleagues (2023). Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia. New England Journal of Medicine.](https://doi.org/10.1056/nejmoa2300709)\n33. [Rachel C. Lynn and colleagues (2019). c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature.](https://doi.org/10.1038/s41586-019-1805-z)\n34. [Julia Carnevale and colleagues (2022). RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature.](https://doi.org/10.1038/s41586-022-05126-w)\n35. [David Steffin and colleagues (2024). Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature.](https://doi.org/10.1038/s41586-024-08261-8)\n36. [Michelle Monje and colleagues (2024). Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature.](https://doi.org/10.1038/s41586-024-08171-9)\n37. [Kymriah tisagenlecleucel first class car t therapy from novartis receives second fda approval treat appropriate rr patients large b cell lymphoma (novartis.com)](https://www.novartis.com/news/media-releases/kymriah-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma)\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Clinical assessment and procedures › Organ and tissue transplantation › Titles A to La*\n\n*Initially written Sep 29, 2026 · Reviewed: Sep 30, 2026 · Edited: Sep 30, 2026; Oct 15, 2026 · Last review: Sep 30, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n", "same_as": [], "url": "https://www.edgepedia.org/adoptive-cell-transfer", "markdown_url": "https://www.edgepedia.org/adoptive-cell-transfer.md", "license": { "name": "Edgepedia Community License 1.0", "url": "https://www.edgepedia.org/edgepedia/license", "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.", "spdx": "LicenseRef-Edgepedia-Community-1.0" }, "credit": "\"Adoptive cell transfer\", Edgepedia (EdgeChat), https://www.edgepedia.org/adoptive-cell-transfer. Edgepedia Community License 1.0.", "credit_md": "\"[Adoptive cell transfer](https://www.edgepedia.org/adoptive-cell-transfer)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/adoptive-cell-transfer](https://www.edgepedia.org/adoptive-cell-transfer). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).", "credit_html": "\"Adoptive cell transfer\", Edgepedia (EdgeChat), https://www.edgepedia.org/adoptive-cell-transfer. Edgepedia Community License 1.0.", "speakable": "Adoptive cell transfer is an immunotherapy in which a patient's own or donor immune cells are modified and reinfused to treat cancer, pioneered by Steven Rosenberg in 1985." }